Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (
                    <scp>MOXIe</scp>
                    Study)

R. Lynch, David; P. Chin, Melanie; B. Delatycki, Martin; H. Subramony, S.; Corti, Manuela; Chad Hoyle, J.; Boesch, Sylvia; Nachbauer, Wolfgang; Mariotti, Caterina; D. Mathews, Katherine; Giunti, Paola; Wilmot, George; Zesiewicz, Theresa; Perlman, Susan; Goldsberry, Angie; O'Grady, Megan; J. Meyer, Colin

doi:10.1002/ana.25934

Public

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia ( MOXIe Study)

Shared by NobleBlocks on Nov 5, 2020 • 12:00 AM UTC

Authors:

David R. Lynch

Melanie P. Chin

Martin B. Delatycki

Abstract

Objective Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxolo...

Discussions